Ezetimibe as a potential treatment for non alcoholic fatty liver disease: is the intestine a modulator of hepatic insulin sensitivity and hepatic fat accumulation?
Non-alcoholic fatty liver disease (NAFLD) is the hepatic component of the metabolic syndrome and is known to be associated with significant insulin resistance and increased risk of cardiovascular disease. .Ezetimibe, an inhibitor of intestinal cholesterol absorption, has been shown to inhibit Nieman...
Main Authors: | Ahmed, Mohamed H. (Author), Byrne, Christopher D. (Author) |
---|---|
Format: | Article |
Language: | English |
Published: |
2010-08.
|
Subjects: | |
Online Access: | Get fulltext |
Similar Items
-
The role of hepatic fat accumulation in pathogenesis of non-alcoholic fatty liver disease (NAFLD)
by: Bengmark Stig, et al.
Published: (2010-04-01) -
Ezetimibe decreased nonalcoholic fatty liver disease activity score but not hepatic steatosis
by: Hyo Young Lee, et al.
Published: (2019-03-01) -
The Role of Hepatic Fat Accumulation in Glucose and Insulin Homeostasis—Dysregulation by the Liver
by: Amalie London, et al.
Published: (2021-01-01) -
Does Diacylglycerol Accumulation in Fatty Liver Disease Cause Hepatic Insulin Resistance?
by: Brian N. Finck, et al.
Published: (2015-01-01) -
Correlation of Mesenteric Fat Thickness and Liver Fat Accumulation in Non-alcoholic Fatty Liver Disease
by: Farzad Moradhaseli, et al.
Published: (2010-09-01)